Already registered companies: Click Here
Programme Anglonordic Biotech Conference IV
09.00 – 09.30 |
Registration and coffee |
|---|---|
| 09.30 – 09.40 | Introduction by the Chairman of the Conference |
| 09.40 – 09.50 | Welcome on behalf of Mr Staffan Carlsson, Ambassador of Sweden |
| 09.50 – 10.25 | Partnering Pitches |
| 10.25 – 10.50 | Collaboration Strategy at Merck to Facilitate Drug Discovery and Development - Examples from Early and Late Stage Deals and Acquisitions - Hans Boström, Director, Scientific Liaison, Licensing and External Research, Europe, Merck Sharp & Dohme |
10.50 – 12.10 |
The Next Thing in Drug Discovery |
| 12.10 – 13.10 | Lunch |
| 13.10 – 13.45 | Partnering Pitches - Galapagos - David Phillips, Senior Vice President - Lytix Biopharma - Øystein Rekdal, CEO - Cresset BioMolecular Discovery - Dr Sally Rose, Director |
| 13.45 – 14.15 | Top 10 tips from Bird & Bird on M&A and Corporate Transactions in the Life Science Sector - Matt Dennis, Partner, London & Sally Shorthose, Partner, London, Ulf Lundberg, Head of Life Science Sector Group, Stockholm, Bird & Bird |
| 14.15 – 14.45 | Early Phase Drug Development - Yvonne Lech, CEO, Capio Diagnostik and Knut T. Smerud, CEO, Smerud Medical Research International |
| 14.45 – 15.15 | Keeping Your Options Open: How European Biotechnology Companies Can Best Prepare for a Dual Exit Strategy – Dr Regina Hodits, Partner in the Life Science Sector, Atlas Venture LLP |
| 15.15 – 15.45 | Q&A and Conclusions |
| 15.45 – 19.00 | Buffet and Drinks |